Page last updated: 2024-12-07

3-(4-methoxybenzoyl)propionic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(4-methoxybenzoyl)propionic acid, also known as 4-methoxybenzoylpropionic acid, is an organic compound with the molecular formula C11H12O4. It is a white solid that is soluble in water and organic solvents. The compound is typically synthesized through Friedel-Crafts acylation of anisole with propionic acid. It exhibits diverse biological properties and has been investigated for its potential applications. For example, 3-(4-methoxybenzoyl)propionic acid has been explored as a potential anti-inflammatory agent, displaying activity in inhibiting inflammatory processes in various models. It has also been studied for its effects on cell growth and proliferation, suggesting possible anticancer properties. The compound's structural features, particularly the methoxy group and the benzoyl moiety, contribute to its diverse biological activities. 3-(4-methoxybenzoyl)propionic acid is investigated for its potential therapeutic applications in treating inflammatory conditions, cancer, and other diseases.'
```

3-(4-methoxybenzoyl)propionic acid: a selectin inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID76613
CHEMBL ID1501712
SCHEMBL ID503582
MeSH IDM0304237

Synonyms (56)

Synonym
BB 0218541
4-(4-methoxyphenyl)-4-oxo-butyric acid
nsc 12472
einecs 221-593-4
benzenebutanoic acid, 4-methoxy-gamma-oxo-
ai3-07210
3153-44-4
nsc12472
nsc-12472
smr000097616
MLS000120774
inchi=1/c11h12o4/c1-15-9-4-2-8(3-5-9)10(12)6-7-11(13)14/h2-5h,6-7h2,1h3,(h,13,14
SR-01000623509-2
3-(4-methoxybenzoyl)propionic acid, 97%
MAYBRIDGE1_002003 ,
OPREA1_054996
STK202166
4-(4-methoxyphenyl)-4-oxobutanoic acid
AKOS000148572
HMS547D01
3-(4-methoxybenzoyl)propionic acid
4-(4-methoxyphenyl)-4-oxobutyric acid
M1383
EN300-60118
CHEMBL1501712
HMS2258F03
CCG-50522
FT-0613683
AB00273
4-(4-methoxy-phenyl)-4-oxo-butyric acid
3-(4-methoxylbenzoyl)propionic acid
4-(4-methoxyphenyl)-4-oxo-butanoic acid
4-oxo-4-(4-methoxyphenyl)butanoic acid
4-methoxy-gamma-oxobenzenebutanoic acid
SCHEMBL503582
mfcd00002795
SY031613
3-(p-methoxybenzoyl)-propionic acid
.beta.-(p-methoxybenzoyl)propionic acid
benzenebutanoic acid, 4-methoxy-.gamma.-oxo-
4-(4-methoxyphenyl)-4-oxobutanoic acid #
3-(4-methoxybenzoyl)propanoic acid
J-513534
DTXSID50185432
S10173
J-018454
AS-17362
benzenebutanoic acid, 4-methoxy-g-oxo-
CS-W015225
beta-(4-methoxybenzoyl)propionic acid
3-(p-methoxybenzoyl)propionic acid
propionic acid, 3-p-anisoyl-
SN7GHW7M6E
3-(p-methoxybenzoyl)propanoic acid
3-p-anisoylpropionic acid
Z285137194
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's4 (44.44)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.26 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]